Abstract
Collategene® Intramuscular Injection 4 mg is a plasmid DNA encoding human HGF（Hepatocyte growth factor） gene （cDNA）, and is the first gene therapy product in Japan. Collategene is transcribed and translated in the cells at the injection site of muscle, thereby expressing and secreting HGF. The angiogenic effect of HGF develops collateral to improve ischemia. Collategen is the first gene therapy in Japan to provide a novel and innovative treatment for severe diseases that require treatment but have no cure. Collategene is indicated for gene therapy for the patient who has arteriosclerosis obliterans and Buerger’s disease accompanying “critical limb ischaemia for who is not amenable surgical revascularization,” and no effective treatments available. This article describes the characteristics of this drug and clinical results.
